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TECHNICAL NOTE
Transposition of the brachial vein: A new source
for autologous arteriovenous fistulas
Hernan A. Bazan, MD, and Harry Schanzer, MD, Bronx, NY
Increasing the prevalence of arteriovenous fistula over arteriovenous synthetic graft is critical for decreasing the morbidity
and costs of dialysis patients. This is highlighted in the guidelines set forth by The National Kidney Foundation-Dialysis
Outcomes Quality Initiative (NKF-DOQI), which encourage the increased use of autogenous vein in fistula creation. In
addition to the basilic and cephalic veins, another source of autogenous vein is the brachial vein, a deep vein of the upper
arm. Here we describe 2 patients with absence of adequate superficial veins, in whom a transposed brachial vein was used
for the creation of an arteriovenous fistula. (J Vasc Surg 2004;40:184-6.)Brescia and Cimino1 first described the creation of an
arteriovenous fistula (AVF) for hemodialysis in 1966. Since
that time, improvements in the management of end-stage
renal disease (ESRD) and a continued lack of sufficient
suitable transplant organs have increased the need for arte-
riovenous (AV) access. Because of this increased demand
for AV access, synthetic material such as bridge grafts
between the artery and vein has become the most fre-
quently used material in vascular accesses performed in the
United States, with the rate of use approaching 70% to 80%
in the late 1990s.2 This is in spite of the fact that, when
compared with AVFs, these arteriovenous grafts (AVGs)
have higher rate of complications and decreased patency.3
In response to the increasing number of AVGs as
opposed to autogenous fistula formation, the National
Kidney Foundation published a set of clinical practice
guidelines in 1997.4 This Dialysis Outcomes Quality Ini-
tiative (DOQI) document stresses the importance of re-
versing this trend as a way of improving AV access quality.
One way of extending the availability of autologous vein is
through the use of transposed basilic vein. Dagher et al5
first described this technique in 1976. Indeed, since publi-
cation of the DOQI recommendations, there has been
renewed interest in this technique.2
In this report we present 2 cases in which the brachial
vein was used in a transposed fashion as an AVF and
propose its use when other more conventional forearm or
upper arm superficial veins are not suitable for AVF cre-
ation.
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Preoperative vein mapping is done whenever clini-
cally indicated, such as in patients with no obviously
useful superficial veins or patients who have previously
undergone upper-arm fistula creation. An incision under
local anesthesia is made over the course of the brachial
artery in the antecubital fossa and, after dissection of
the brachial artery and vein, the incision is extended
longitudinally following the course of the brachial
vein. In order to avoid necrosis of the wound, care is
taken to avoid producing flaps in the incision. The
brachial vein is dissected and all of its tributaries are
individually ligated with 4-O silk suture ties. When
branches are very wide and short, suture ligation with
4-0 silk is done.
As in basilic vein transposition,5 in order to be able to
tunnel it laterally with enough length, the brachial vein
has to be harvested down into the antecubital area, about
3 cm distal in the forearm. The vein is ligated at this level
and divided proximally. The size of the nondistended
brachial vein is about 4 to 5 mm in diameter and may
increase to 6 to 8 mm with hydrostatic dilatation. The
vein is distended with Ringers lactate–heparinized solu-
tion and marked with methylene blue for orientation and
avoidance of torsion (Fig 1). This deep arm vein is then
transposed subcutaneously through a tunnel lateral to
the incision. In obese patients, care has to be given to
make a very superficial tunnel. The anastomosis between
the transposed brachial vein and the distal brachial artery
is performed in an end-to-side fashion, using 6-O
polypropylene sutures (Fig 2). After flow is established, a
thrill is easily palpated throughout the course of the
transposed brachial vein. A period of 8 weeks is allowed
for the fistula to mature prior to its being used for
hemodialysis.
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A 65-year-old man with ESRD secondary to diabetes in
need of chronic AV access had previously undergone a
radiocephalic AVF that failed soon after its construction.
The plan was made to proceed with a basilic vein transpo-
sition, but open exploration found no suitable basilic vein.
However, a well-developed brachial vein was found run-
ning along the brachial artery and this was used to create an
AVF. After 2 months, the AVF matured and it has since
been used successfully for hemodialysis access without any
significant symptom or sign of venous hypertension, such as
severe arm swelling, skin pigmentation or ulceration.
A 75-year-old male with ESRD secondary to hyperten-
sion underwent preoperative vein mapping, which demon-
strated small cephalic and basilic veins and no suitable veins
in the forearm. An AVG placement was planned for this
patient. However, during exploration, the brachial vein was
found to be of good caliber. A transposed brachial vein to
brachial artery anastomosis was created. The fistula ma-
tured in 2 months and has been used successfully for
hemodialysis. No manifestations of venous hypertension
were present in this patient either. After 1 year, both
patients have well-functioning AV fistulas.
DISCUSSION
Ever since the report of the first surgically created arterio-
venous fistula for hemodialysis 4 decades ago, vascular access
has remained the Achilles heal of chronic hemodialysis. AVF
using autogenous vein remains the optimal vascular access for
hemodialysis. A recent assessment of the impact of the DOQI
clinical practice guidelines found that the incidence of simple
fistula creation versus permanent catheter placement for he-
modialysis has increased from pre-DOQI guidelines in 1994
to 1999 by 45%.6 Unfortunately, this report does not contain
any data discerning native AVF creation in comparison to
AVG placement. However, a recent report comparing the
rates of AVF use in the United States with those in Europe
from 1996 through 2000 found that large differences in
vascular access use exist.7 In Europe, 80% of AV accesses were
constructed as AVFs while in the USA only 24% were native
fistulas. These large differences in vascular access between the
United States and Europe demonstrate that much work re-
mains to be done in the United States toward increasing the
prevalence of autogenous vein use for AVF creation.
The use of preoperative mapping8 and basilic upper
arm vein transposition has helped to increase the frequency
of AVF creation. Another source of autogenous vein is the
deep veins of the arm. In this work, we report the use of the
brachial vein as an autogenous AVF. This type of fistula,
although time consuming and technically challenging, al-
lows for further increase in the use of autologous conduit.
The deep location of the brachial vein protects it from
venipuncture and scarring. This is particularly applicable for
patients who have had peripherally inserted central cathe-
ters, which often obliterate the basilic veins. We believe that
the use of a transposed brachial vein in the creation of an
AVF may be especially useful in patients who lack suitablesuperficial veins. Indeed, over 10 years ago this was men-
tioned by Rivers et al9 in their experience with the basilic
vein transposition. Concerns about onset of venous hyper-
tension after use of the brachial vein as an autologous
conduit for AVF are reasonable. In the 2 cases presented
here, nevertheless, this was not a problem. This situation
may be analogous to the experience observed with the use
of the femoral vein as arterial bypass substitute,10,11 where
no significant sign of clinical venous hypertension, such as
severe limb swelling, skin pigmentation, or ulceration, was
observed. In these 2 circumstances, the rich venous collat-
eral circulation and the common presence of paired brachial
veins may compensate for the decrease in venous outflow
produced by the use of the deep vein. Nevertheless, close
clinical follow-up is prudent. In a retrospective review of 25
Fig 1. The brachial vein, a deep upper arm vein running along the
course of the brachial artery, has been dissected, all of its tributaries
ligated individually with 4-O silk sutures, and distended with
heparinized Ringers lactate. Prior to transposition of the brachial
vein, it is important to mark the vein with methylene blue along its
length in order to avoid twisting, a common cause of outflow
obstruction and early graft failure.
Fig 2. Schematic representation of a transposed brachial vein-
brachial artery AVF. The brachial vein is transposed subcutane-
ously through a tunnel lateral to the incision and an anastomosis is
done with the distal brachial artery in an end-to-side fashion.
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with autologous transposed superficial femoral vein, 1 pa-
tient required amputation due to a compartment syn-
drome, presumably due to venous hypertension.12 With
regards to the technique presented here, it remains to be
seen whether, in larger series, the long-term patency rate
and incidence of complications are comparable to those for
the more traditional autologous AVFs.
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